Genetic diversity facilitates cancer therapy

(Max-Planck-Gesellschaft) Cancer patients with more different HLA genes respond better to treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: Available online 10 December 2019Source: International Journal of PharmaceuticsAuthor(s): Li Cao, Qiyu Li, Zhen Tong, Yutong Xing, Keyuan Xu, Jessica Yijia Wang, Wenjing Li, Jianhua Zhao, Liqing Zhao, Zhangyong HongAbstractHuman epidermal growth factor receptor 2 (HER2) is an attractive target for cancer therapy, although a large fraction of tumors that express HER2 may still resist first-line therapies. Immunotoxins with antibodies that are armed with extremely potent cytotoxic toxin molecules may provide an important solution to this problem. In this work, we constructed three new anti-HER2 immunotoxins...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: 9 December 2019Source: Cancer Cell, Volume 36, Issue 6Author(s): Detlev Boison, Gennady G. YegutkinAdenosine is a key metabolic and immune-checkpoint regulator implicated in the tumor escape from the host immune system. Major gaps in knowledge that impede the development of effective adenosine-based therapeutics include: (1) lack of consideration of redundant pathways controlling ATP and adenosine levels; (2) lack of distinction between receptor-dependent and -independent effects of adenosine, and (3) focus on extracellular adenosine without consideration of intracellular metabolism and compartmentalizati...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Authors: Mabonga L, Kappo AP Abstract Small nuclear ribonucleoprotein polypeptide G (SNRPG), often referred to as Smith protein G (SmG), is an indispensable component in the biogenesis of spliceosomal uridyl-rich small nuclear ribonucleoprotein particles (U snRNPs; U1, U2, U4 and U5), which are precursors of both the major and minor spliceosome. SNRPG has attracted significant attention because of its implicated roles in tumorigenesis and tumor development. Suggestive evidence of its varying expression levels has been reported in different types of cancers, which include breast cancer, lung cancer, prostate cancer ...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Lantheus Medical Imaging parent company Lantheus Holdings has agreed to supply...Read more on AuntMinnie.comRelated Reading: Lantheus posts lower Q3 results Lantheus to acquire Progenics Lantheus posts mixed Q2, 6-month results Lantheus touts contrast echo study at ASE 2019 Lantheus inks radiopharma deal with NanoMab
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Healthcare insurance companies should value PET imaging and its cost-effective...Read more on AuntMinnie.comRelated Reading: CMS final rule for MPFS could cost radiology $5B CMS gets pushback on PET fee cuts PSMA-PET/CT most effective for recurrent prostate cancer Editorial slams NRC plan to expand radiopharmaceutical users PET tracers help guide breast cancer therapies
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
ConclusionsAt the 400 μg dose level no substantial changes in PD parameters were noted. Extrapolating from pre-clinical data, the dose examined in this cohort was too low to achieve the Se plasma concentration (≥ 5 μM) expected to elicit significant PD effects. Recruitment of a subsequent cohort at higher doses to exceed this PK threshold is planned.
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
ConclusionThe prepared pH/redox dual-sensitive PPM enhanced the chemotherapy effect on the tumor site while reducing the physiological toxicity of DOX.Graphical Abstract
Source: Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
DNA double-strand breaks (DSBs) are highly deleterious, with a single unrepaired DSB being sufficient to trigger cell death. Compared to healthy cells, cancer cells have a higher DSB burden due to oncogene-induced replication stress and acquired defects in DNA damage response (DDR) mechanisms. Consequently, hyperproliferating cancer cells rely on efficient DSB repair for their survival. Moreover, augmented DSB repair capacity is a major cause of radio- and chemoresistance and, ultimately, cancer recurrence. Although inherited DDR defects can predispose individuals to develop certain cancers, the very same vulnerability may...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We present a contemporary analysis of risk of fatal stroke among more than 7.5 million cancer patients and report that stroke risk varies as a function of disease site, age, gender, marital status, and time after diagnosis. The risk of stroke among cancer patients is two times that of the general population and rises with longer follow-up time. The relative risk of fatal stroke, versus the general population, is highest in those with cancers of the brain and gastrointestinal tract. The plurality of strokes occurs in patients older than 40 years of age with cancers of the prostate, breast, and colorectum. Patients of any ag...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Abstract Malignant cells frequently demonstrate an oncogenic-driven reliance on glycolytic metabolism to support their highly proliferative nature. Overexpression of pyruvate dehydrogenase kinase (PDK) may promote this unique metabolic signature of tumor cells by inhibiting mitochondrial function. PDKs function to phosphorylate and inhibit pyruvate dehydrogenase (PDH) activity. Silencing of PDK expression has previously been shown to restore mitochondrial function and reduce tumor cell proliferation. High dose Vitamin B1, or thiamine, possesses antitumor properties related to its capacity to reduce PDH phosphoryla...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics